Inhibitor Therapeutics, Inc.
INTI
$0.049
-$0.0006-1.21%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.48% | -11.19% | -3.66% | 4.45% | 36.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.11% | 0.20% | 7.41% | 34.87% | 81.84% |
| Operating Income | -8.11% | -0.20% | -7.41% | -34.87% | -81.84% |
| Income Before Tax | -14.15% | -3.66% | -10.34% | -129.22% | -127.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.15% | -3.66% | -10.34% | -129.37% | -127.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.15% | -3.66% | -10.34% | -129.37% | -127.22% |
| EBIT | -8.11% | -0.20% | -7.41% | -34.87% | -81.84% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -13.64% | -3.24% | -10.23% | -168.58% | -159.26% |
| Normalized Basic EPS | -15.60% | -4.35% | -10.91% | -47.37% | -105.66% |
| EPS Diluted | -13.64% | -3.24% | -10.23% | -176.82% | -165.43% |
| Normalized Diluted EPS | -15.60% | -4.35% | -10.91% | -47.37% | -105.66% |
| Average Basic Shares Outstanding | 0.16% | 0.18% | 0.18% | -18.96% | -34.73% |
| Average Diluted Shares Outstanding | 0.16% | 0.18% | 0.18% | -18.96% | -34.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |